Standout Papers

Sotagliflozin in Patients with D... 2008 2026 2014 2020 745
  1. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  2. Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline (2012)
    Guillermo E. Umpierrez, Richard Hellman et al. The Journal of Clinical Endocrinology & Metabolism
  3. Excess Mortality among Persons with Type 2 Diabetes (2015)
    Mauro Tancredi, Annika Rosengren et al. New England Journal of Medicine
  4. Glycemic Control and Excess Mortality in Type 1 Diabetes (2014)
    Marcus Lind, Ann‐Marie Svensson et al. New England Journal of Medicine
  5. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials (2008)
    Jay S. Skyler, Richard M. Bergenstal et al. Diabetes Care
  6. The Obesity Paradox (2005)
    Jeptha P. Curtis, Yongfei Wang et al. Archives of Internal Medicine
  7. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs (2017)
    Mikhail Kosiborod, Matthew A. Cavender et al. Circulation
  8. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials (2022)
    Muthiah Vaduganathan, Kieran F. Docherty et al. The Lancet
  9. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions (2014)
    Thomas T. Tsai, Uptal D. Patel et al. JACC: Cardiovascular Interventions
  10. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update (2019)
    Shannon M. Dunlay, Michael M. Givertz et al. Circulation
  11. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association (2016)
    Biykem Bozkurt, David Aguilar et al. Circulation
  12. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes (2020)
    Sandeep R. Das, Brendan M. Everett et al. Journal of the American College of Cardiology
  13. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors (2018)
    Hiddo J.L. Heerspink, Mikhail Kosiborod et al. Kidney International
  14. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study (2019)
    Hiddo J.L. Heerspink, Avraham Karasik et al. The Lancet Diabetes & Endocrinology
  15. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial (2021)
    Scott D. Solomon, Rudolf A. de Boer et al. European Journal of Heart Failure
  16. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure (2021)
    Michael E. Nassif, Mohammed Qintar et al. Circulation
  17. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial (2022)
    John A. Spertus, Mary C. Birmingham et al. Nature Medicine
  18. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction (2021)
    David D. Berg, Pardeep S. Jhund et al. JAMA Cardiology
  19. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF (2021)
    James P. Curtain, Kieran F. Docherty et al. European Heart Journal
  20. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial (2022)
    Jan Biegus, Adriaan A. Voors et al. European Heart Journal
  21. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials (2024)
    Mikhail Kosiborod, John Deanfield et al. The Lancet
  22. Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020 (2023)
    John W. Ostrominski, Suzanne V. Arnold et al. JAMA Cardiology
  23. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial (2024)
    John Deanfield, Subodh Verma et al. The Lancet
  24. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial (2024)
    Richard E. Pratley, Katherine R. Tuttle et al. Journal of the American College of Cardiology
  25. Semaglutide and NT-proBNP in Obesity-Related HFpEF (2024)
    Mark C. Petrie, Barry A. Borlaug et al. Journal of the American College of Cardiology
  26. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials (2024)
    Kavita Sharma, Barry A. Borlaug et al. European Heart Journal

Immediate Impact

90 standout
Sub-graph 1 of 19

Citing Papers

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
From geroscience to precision geromedicine: Understanding and managing aging
2025 Standout
1 intermediate paper

Works of Mikhail Kosiborod being referenced

SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
2022 Standout
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
2022
and 1 more

Author Peers

Author Last Decade Papers Cites
Mikhail Kosiborod 11596 8746 4140 422 20.9k
Neil R Poulter 15008 15239 8727 439 33.8k
David Fitchett 12416 5737 6610 198 18.0k
Stephen MacMahon 6831 15926 4356 246 26.7k
Itamar Raz 14772 6237 5439 370 25.1k
Luís M. Ruilope 9780 19422 4682 754 29.8k
Michel Marre 8347 3658 3239 419 16.6k
Johannes F.E. Mann 13170 10175 5887 275 28.7k
David M. Herrington 6709 11755 4269 410 25.8k
Hans‐Henrik Parving 8667 8300 2177 231 20.2k
Sverre E. Kjeldsen 10798 26590 6837 513 35.2k

All Works

Loading papers...

Rankless by CCL
2026